Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines

E-ISSN： 1875-6913|11|1|31-41

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.11, Iss.1, 2013-03, pp. : 31-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S. Perry Caroline M.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio Mottolese Marcella Fabi Alessandra

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

‘Simply stunning’ – trastuzumab in HER2-positive breast cancer

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 631-634

Informa Healthcare

Access to resources Recommend Favorite

Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer

Inpharma, Vol. 1, Iss. 1485, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Trastuzumab cost effective in HER2-positive breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite